23. Clinical Trial When XELJANZ (tofacitinib) was administered as part of a clinical trial for this rheumatoid arthritis treatment, 1336 subjects were given 5 mg doses of the drug, and here are the numbers of adverse reactions: 57 had headaches, 21 had hypertension, 60 had upper respiratory tract infections, 51 had nasopharyngeal 53 had diarrhea. Does any one of these adverse reactions appear to be much more common than the others? (Hint: Find the relative frequencies using only the adverse reactions, not the total number of treated subjects.)